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Abstract
Background: To evaluate the impact of 68Ga-DOTATOC-PET on treatment planning and sparing of normal tissue in
the treatment of skull base meningioma with advanced photons and protons.
Methods: From the institutional database consisting of 507 skull base meningiomas 10 patients were chosen
randomly for the present analysis. Target volume definition was performed based on CT and MRI only, as well as
with additional 68Ga-DOTATOC-PET. Treatment plans were performed for Intensity Modulated Radiotherapy (IMRT)
and proton therapy using active raster scanning on both target volumes. We calculated doses to relevant organs at
risk (OAR), conformity indices as well as differences in normal tissue sparing between both radiation modalities
based on CT/MRI planning as well as CT/MRI/PET planning.
Results: For photon treatment plans, PET-based treatment plans showed a reduction of brain stem Dmax and
Dmedian for different levels of total dose. At the optic chiasm, use of
68Ga-DOTATOC significantly reduces Dmax;
moreover, the Dmedian is reduced in most cases, too. For both right and left optic nerve, reduction of dose by
addition of 68Ga-DOTATOC-PET is minimal and depends on the anatomical location of the meningioma. In protons,
the impact of 68Ga-DOTATOC-PET is minimal compared to photons.
Conclusion: Addition of 68Ga-DOTATOC-PET information into treatment planning for skull base meningiomas has a
significant impact on target volumes. In most cases, PET-planning leads to significant reductions of the treatment
volumes. Subsequently, reduced doses are applied to OAR. Using protons, the benefit of additional PET is smaller since
target coverage is more conformal and dose to OAR is already reduced compared to photons. Therefore, PET-imaging
has the greatest margin of benefit in advanced photon techniques, and combination of PET-planning and high-
precision treatment leads to comparable treatment plans as with protons.
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Background
Radiation therapy (RT) is a central treatment alterna-
tive in patients with skull base meningiomas [1].
Since neurosurgical resection can be associated with
significant morbidity due to the complex anatomical
structures of the skull base, especially if complete re-
sections are anticipated, RT is generally associated
with very low toxicity and local control rates are above
80–90% even after 10 or 20 years [2, 3]. However, the
intricate anatomy of the skull base also poses a
challenge to the radiation oncologist: The goal is the
delivery of necessary doses to the target volumes,
while keeping the dose outside the target volumes,
especially to Organs at Risk (OAR) as low as possible
[4, 5]. Therefore, advanced RT techniques such as
stereotactic radiotherapy, intensity modulated radio-
therapy (IMRT) or particle therapy are recommended
for skull base lesions.
The standard imaging protocols for treatment plan-
ning of skull base meningiomas include contrast-
enhanced CT and MRI. Previously, it has been shown
that addition of 68Ga-DOTATOC-PET can improve
target volume definition [6–13]. Compared to CT or
MRI, 68Ga-DOTATOC PET/CT demonstrated an
improved sensitivity in meningioma detection when
compared to contrast-enhanced MRI. Especially skull
base lesions or meningiomas obscured by imaging arti-
facts or calcifications can be detected more precisely
with additional PET; in cases with uncertain or equivocal
results on MRI 68Ga-DOTATOC-PET-Imaging can
help confirm the diagnosis of meningioma [14]. For
meningiomas with extension into soft tissues, especially
after surgical interventions, PET-planning significantly
reduces treatment volumes; for bony meningiomas, PET-
planning generally enhances detection of the bony lesions
and often leads to a significant enlargement of volumes
[10]. Some authors, such as Graf et al. reported that target
volumes can be reduced overall by about 10% [8, 11].
Additional precision of added 68Ga-DOTATOC-
PET has been reported by using PET-MRI combin-
ation devices minimizing any positioning or matching
errors [9, 12, 14].
Thus, the contribution to target volume reduction has
been shown. However, it is unclear whether this reduc-
tion, does actually result in a meaningful and clinically
reduction of dose to OAR. Moreover, it is unclear of this
modification of target volumes is independent of the ra-
diation technique applied.
Therefore, in the present work we determined the
impact of target volume modification by use of 68Ga-
DOTATOC-PET for RT planning in patients with skull
base meningiomas. We calculated the potential of dose
reduction for different high-precision techniques com-
paring advanced photons to protons.
Methods
Patient characteristics
From the institutional database a group of 10 patients with
skull base meningiomas treated with RT was chosen ran-
domly from a group of 507 patients treated with high-
precision RT [3]. Nine patients were female, one patient
was male. The median age was 58 years (range 42–70 years).
In 8 out of 10 patients histologically confirmed diagnosis of
WHO Grade I meningioma was present, in two patients
diagnosis of low-grade meningioma was imaging based. The
median planning tumor volume (PTV) was 50 cm3 (range
19.2 cm3–218.4cm3). All patients had been treated with RT
as described previously [10, 15]. For treatment planning all
patients had been positioned by an individual mask fixation
either made of Scotch Cast™ or mask systems made of
thermoplastic material as described previously. All patients
had received contrast enhanced CT and MRI, as well as
68Ga-DOTATOC-PET imaging for RT treatment planning.
The study was approved by the Ethic’s Committee of the
Medical Faculty, University of Heidelberg.
Target volume
Target volumes were re-evaluated from all 10 patients and
two sets of gross tumor volumes (GTV) were defined. CT
and MRI at 1-3 mm slice slickness were used for treat-
ment planning and therefore for the present analysis. After
initial automatic and additional manually fine-tuned
image fusion of CT, MRI and 68Ga-DOTATOC-PET for
each patient, target volumes were drawn manually from
experienced radiation oncologists with expertise in the
field of radiation oncology and nuclear medicine. One
volume was based on contrast-enhanced CT and MRI
imaging only; the second volume additionally included
68Ga-DOTATOC-PET information. Figure 1 shows all
three imaging modalities in a typical patient with a skull
base meningioma. We followed our imaging protocols as
published previously [6, 10, 14, 16]. We defined the
meningioma-SUV for each patient: For that, typical
meningioma tissue on MRI/CT was identified on the
PET- image and the tracer uptake for that region was doc-
umented. Then, we calculated the SUVmax for meningi-
oma tissue in relation to the tracer-uptake in normal
tissue. By this procedure we defined a specific individual
meningioma-SUV for each patient by referencing the
SUVmax to a region of typical meningioma tissue visible in
CT and MR. The median patients-specific value was 58%
(range 54% – 62%). Additionally a clinical target volume
(CTV) was determined adding 1 mm safety margin, as
well as a planning target volume as described previously
[3]. The PTV was added based on institutional standards.
Treatment planning
For all patients, we calculated treatment plans for inten-
sity modulated radiotherapy (IMRT) as well as proton
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therapy using the active raster scanning method. For
IMRT planning the Oncentra Masterplan (Nucletron,
Elekta, Stockholm, Sweden) software was used as
described previously [3]. A template of 9 beam angles at
40 ° distances was used and modified as needed for opti-
mal target volume coverage and OAR sparing. For pro-
ton therapy, the syngo RT Planning System (Siemens,
Erlangen, Germany) was used. All plans were calculated
using horizontal proton beams. The use of horizontal
proton beams was generally used at the time of the ana-
lysis to treat most skull base lesions at the Heidelberg
Ion beam Therapy Center and thus used for this ana-
lysis, which was performed also for internal treatment
optimization [15].
All plans were optimized to a target dose of 54 Gy in 1.
8 Gy single fractions as well as plans for 57.6 Gy in 1.8 Gy
single fractions based on the two main published dosing
concepts for skull base meningiomas [2, 3]. The aim was
to cover 95% of the treatment volume with at least 90% of
the median prescribed dose following ICRU (international
commission on radiation units & measurements) guide-
lines for treatment planning and reporting.
For both modalities, treatment plan optimization and
OAR sparing followed the QUANTEC (Quantitative
Analyses of Normal Tissue Effects in the Clinic) recom-
mendations to remain below a maximal toxicity rate of
5% at 5 years. For example, for brain stem constraints a
maximal dose of 59 Gy at 10 cm3 and/or 54 Gy to the
whole brain stem volume was allowed [17]. The
maximal dose to the optic nerves and chiasm was set at
55 Gy [18]. Highest priority was dose to the brain stem,
followed by the optic system. Treatment planning was
optimized multiparametrically until the best compromise
between target volume coverage and OAR sparing was
achieved. All plans were reviewed and accepted by a
team of experienced radiation oncologists. (12).
Figure 2 depicts the differences in target volumes and
corresponding IMRT treatment plans of a typical skull
base meningioma case.
Statistical analysis
To assess doses to OAR, we calculated Dmax and Dmedian
of brain stem, chiasm and left and right optic nerves.
Descriptive statistical analysis was performed using
SPSS-IBM Version 21. Differences were described using
the Wilcoxon-text for paired samples and the p-value was
generated for median and maximal doses to each OAR.
Results
Skull base meningioma treatment plans with IMRT: Dose
to OAR
For plans calculated for a total dose of 54 Gy, in 9 out of
10 patients PET-based target volumes lead to a reduc-
tion of brain stem Dmax which was highly significant at
p = 0.0097. In 8 out of 10 patients, a reduction of the
brain stem Dmedian was observed which was also signifi-
cant at p = 0.037. Results are shown in Table 1.
Table 2 shows dose calculations for plans with 57.6 Gy
IMRT; total dose reduction of Dmax could be achieved in
8 out of 10 patients (p = 0.013); for Dmedian the IMRT
plans of 6 out of 10 patients showed a reduced dose
(p = 0.241).
For the optic chiasm, in treatment plans calculated for
total dose of 54 Gy, 9 out of 10 patients had a reduction
of Dmax to the optic chiasm when treatment planning in-
cluded 68Ga-DOTATOC-PET (p = 0.007). Moreover,
Dmedian was reduced in seven out of 10 patients however
not statistically significant (p = 0.23). When the total
dose was increased to 57.6 Gy, 8 out of 10 patients had
a reduced Dmax to the optic chiasm based on PET-
planning (p = 0.032) and the Dmedian was reduced in 9
out of 10 patients (p = 0.007) which was significant in
both cases.
For both right and left optic nerve, reduction of dose
by addition of 68Ga-DOTATOC-PET is minimal
compared to the impact observed from the brain stem
and optic chiasm. However, the impact of PET depends
clearly on the anatomical location of the meningioma.
For large skull base lesions, one (or both) optic nerves
Fig. 1 Imaging of a typical skull base meningioma on a contrast-enhanced CT, b contrast-enhanced MRI and c 68Ga-DOTATOC-PET
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Table 1 Dose to the organs at risk (OAR) in IMRT treatment







Dmax 52.4 (39.8–55.3) 51.4 (39.7–54.7) 0.007*
Dmedian 11.9 (2.8–22.4) 5.5 (3.7–16.1) 0.037*
Optic Chiasm
Dmax 52.5(5.7–55.2) 51.0 (5.0–53.5) 0.007*
Dmedian 39.9 (2.8–53.5) 37.9 (2.4–49.9) 0.203
Left optic nerve
Dmax 53.8 (3.1–56.1) 52.3 (3.1–54.6) 0.017*
Dmedian 40.9 (1.5–52.6) 37.1 (1.5–52.9) 0.063
Right optic nerve
Dmax 49.5 (1.5–55-7) 48.4 (1.5–55.0) 0.022*
Dmedian 28.2 (0.8–54.0) 24.7 (0.8–53.2) 0.047*
*Significant difference <0.05
Fig. 2 Target volume based on CT and MRI a and target volume based on CT, MRI as well as 68Ga-DOTATOC-PET b. Images c and d show the
corresponding treatment plans with photon IMRT. Image e shows the Dose-Volume-Histogram comparing dose to the target and to OAR
Table 2 Dose to the organs at risk (OAR) in IMRT treatment







Dmax 55.1 (47.0–58.1) 54.7 (43.2–58.72 0.013*
Dmedian 13.4 (3.0–21.3) 10.33 (2.8–22.4 0.241
Optic Chiasm
Dmax 53.1(7.3–57.9) 51.8 (4.2–57.5) 0.032*
Dmedian 42.6 (3.36–51.0) 41.0 (2.8–53.5) 0.007*
Left optic nerve
Dmax 54.5 (5.9–58.7) 53.6 (2.3–58.6) 0.036*
Dmedian 42.4 (2.2–55.6) 35.3 (1.5–55.7) 0.017*
Right optic nerve
Dmax 52.1 (1.8–56.7) 51.2 (1.6–57.3) 0.037*
Dmedian 33.7 (0.9–54.5) 28.1 (0.9–54.2) 0.013*
*Significant difference <0.05
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are often within or very close to the target volume, thus
the impact observed is only minimal. However, for both
optic nerves, dose reduction is significant with addition
of PET, for 54 Gy plans as well as for 57.6 Gy plans.
When comparing both dosing regimens the margin of
benefit is larger in the 57.6 Gy dataset. Data are
shown in Table 1 for 54 Gy plans, and in Table 2 for
57.6 Gy plans.
Skull base meningioma treatment plans with Protons:
Dose to OAR
Tables 3 and 4 summarize the data for Dmax and Dmedia-
nin proton treatment plans. Both for 54 Gy and for
57.6 Gy the impact of target volume modification by
68Ga-DOTATOC PET information is minimal compared
to IMRT plans. Generally, compared to the IMRT values,
it can be seen that the dose reduction is less with protons
than with IMRT. Generally, only the median dose was
significantly lower with PET-planning. This was true for
all OAR evaluated.
Discussion
By adding 68Ga-DOTATOC-PET to target volume
definition in radiation oncology significant reduction of
target volumes compared to CT and MRI only can be
achieved. The present manuscript describes the potential
to reduce dose to OAR by adding PET to treatment
planning. Modification of target volumes reduces dose to
OAR with photon radiotherapy. The effect is highest when
OAR are not included in the target volumes. For the skull
base tumors evaluated, the greatest benefit is seen for the
brain stem as well as the optic chiasm. For patients treated
with protons, the PET-effect is minimal, mainly because
dose conformality and dose outside the target is already re-
duced due to the physical properties of particle beams.
To optimize the therapeutic window in radiation on-
cology minimizing dose to normal tissue is an essential
aim. Modern RT techniques, such as stereotactic treat-
ment, IMRT or particle therapy continuously led to in-
creased dose conformality to the target together with
reduction of dose to normal tissue; the step from
advanced photons to particle therapy, e.g. protons, is char-
acterized especially by the reduction of the integral dose.
68Ga-DOTATOC-PET has been established for
diagnosis and treatment planning of meningioma.
Afshar-Oromieh et al. have shown in 134 patients inves-
tigated by both modalities that 190 meningiomas were
detected by 68Ga-DOTATOC PET/CT and only 171 by
contrast-enhanced MRI; moreover, they could show that
adding the knowledge from PET-imaging 4 out of 19
meningiomas were only detectable on MRI knowing the
additional information from the PET-imaging; this lead
to an overall detection rate of 92% [6]. For treatment
planning addition of 68Ga-DOTATOC information
modified target volumes significantly: Mostly lesions
extending into soft tissue e.g. parapharyngeal meningiomas,
seem larger on MRI than the real volume as shown on
PET; for bony meningiomas, which are often difficult to
identify by MRI and often only visibly on CT imaging in
bone windows target volumes are enlarged with PET-target
volume definition. However, to date, no prospective trials
comparing target volume definition based on MRI versus
PET have been performed, and most data on radiotherapy
for meningiomas derives from MRI-based treatment plan-
ning. Therefore, one must keep in mind that modifications
in target volumes might potentially convey to changes in
clinical outcome.
Table 3 Dose to the organs at risk (OAR) in proton treatment







Dmax 52.8 (51.2–53.2) 52.8 (51.9–54.6) 0.86
Dmedian 11.7 (0.7–40.1) 5.7 (0.4–35.3) 0.008*
Optic Chiasm
Dmax 52.6 (1.8–53.4) 52.8 (1.81–54.7) 0.767
Dmedian 39.3 (0.3–53.4) 39.7 (0.3–49.4) 0.038
Left optic nerve
Dmax 52.8 (0.4–56.4) 52.7 (0.4–55.7) 0.678
Dmedian 38.2 (0–51.9) 29.9 (0–51.6) 0.008*
Right optic nerve
Dmax 51.6 (0.1–53.0) 51.9 (0.1–54.3) 0.674
Dmedian 16.2 (0–51.2) 6.4 (0–51.2) 0.036*
*Significant difference <0.05
Table 4 Dose to the organs at risk (OAR) in proton treatment







Dmax 54.3 (52.3–56.0) 54.6 (52.4–57.6) 0.859
Dmedian 12.5 (0.7–41.5) 5.7 (0.48–35.8) 0.008*
Optic Chiasm
Dmax 53.4 (1.9–55.8) 53.6 (1.9–55.3) 0.767
Dmedian 42.0 (0.3–51.3) 40.4 (0.3–50.3) 0.139
Left optic nerve
Dmax 53.7 (0.4–57.2) 53.2 (0.4–57.5) 0.953
Dmedian 38.6 (0.0–52.3) 29.9 (0.0–51.9) 0.008
Right optic nerve
Dmax 52.9 (0.2–53.8) 52.7 (0.2–55.2) 0.953
Dmedian 16.3 (0.0–51.3) 7.0 (0.0–51.5) 0.021*
*Significant difference <0.05
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The potential of PET-planning to reduce treatment
volumes and thus potentially increase dose to the target
while reducing dose to OAR has been evaluated only in
few trials. One planning study evaluating FDG-PET/CT
during radiotherapy in patients with esophageal cancer
showed a decreased target volume by addition of
PET-CT during RT. Moreover, the planning study sug-
gested that due to smaller volumes and reduced dose to
OAR doses of up to 66 Gy can be applied safely [19].
However, in contrast to low-grade meningiomas of the
skull base, dose escalation plays a role in lung cancer.
For meningiomas, high local control rates can most
likely not be increased by addition of dose, and in the
past, several studies have shown that even slightly higher
doses (52.2 Gy compared to 57.6 Gy) do not convey into
higher local control rates. Thus, the rationale for dose
sparing to OAR is more likely in terms of long-term risk
reduction, e.g. secondary malignancies or functional
changes. The idea of integral dose reduction is strongly
associated with proton therapy [20]. Due to the physical
properties of protons sparing of normal tissue outside
the target volumes is possible. Several groups have cal-
culated an alleged risk reduction for secondary cancers,
neurocognitive decline or other side effects [21–25].
However, to date, no prospective studies have confirmed
this clinical hypothesis.
Conclusions
In conclusion, the potential to further reduce dose to
OAR with protons is minimal. However, with IMRT, the
benefit is significant for all OAR evaluated. Therefore,
with advanced treatment planning improvement of high-
end IMRT is achieved moving treatment plans closer to
those achieved by particle therapy. Therefore, comparing
of advanced photons with high-end imaging for treatment
planning to proton therapy potentially leads to compar-
able results, in terms of tumor control rates and side ef-
fects. However, this must be confirmed in prospective
clinical trials, of which some are already underway.
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